Mesalazine controlled release - Ferring
Alternative Names: Mesalamine granules - Ferring; Pentasa; Pentasa® controlled release 500mg tablets; Pentasa® prolonged release granules 1g/2g/4g; Pentasa® Sachet; PS-QDLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Ferring Pharmaceuticals
- Developer Ferring Pharmaceuticals; Kyorin Pharmaceutical; Takeda
- Class Aminosalicylic acids; Anti-inflammatories; Antineoplastics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 19 Sep 2018 Ferring Pharmaceuticals completes a phase III trial for Ulcerative Colitis in USA, Bulgaria, Canada, Latvia, Hungary, Mexico, Poland, Russia, Switzerland, Serbia, Ukraine and Belgium (PO, once-daily granules 2g ) (NCT02522780) (EudraCT2015-002558-11)
- 03 Apr 2018 Ferring Pharmaceuticals completes a phase III trial for Ulcerative colitis in USA, Belgium, Bulgaria, Latvia, Mexico, Hungary, Canada, Poland, Russia, Switzerland, Ukraine and Serbia (NCT02522767)